SCHEMBL2320171

SCHEMBL2320171

NS(=O)(=O)NCC(O)c1ccccc1F

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GBA1 P04062 1/20 0.46
MC4R P32245 1/20 0.40
ADRA2C P18825 3/20 0.40
CA2 P00918 3/20 0.40
ADRA2A P08913 2/20 0.40
ADRA2B P18089 2/20 0.40
CA12 O43570 2/20 0.40
CA1 P00915 2/20 0.40
ADRB1 P08588 1/20 0.40
ADRB3 P13945 1/20 0.40
CA7 P43166 1/20 0.40
CA14 Q9ULX7 1/20 0.40
CES2 O00748 1/20 0.39
CES1 P23141 1/20 0.39
GAA P10253 1/20 0.39
PRMT3 O60678 1/20 0.39
ADRA1A P35348 1/20 0.38
ADRA1B P35368 1/20 0.38
CNR2 P34972 1/20 0.38
LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2319918 1.00 GBA1 (0.46) GBA1MC4RADRA2CCA2ADRA2A
SCHEMBL2322513 1.00 GBA1 (0.46) GBA1MC4RADRA2CCA2ADRA2A
SCHEMBL9886713 0.82 GBA1 (0.43) GBA1MC4RCA2CA12CA1
SCHEMBL9886711 0.82 GBA1 (0.43) GBA1MC4RCA2CA12CA1
SCHEMBL9281508 0.82 GBA1 (0.43) GBA1MC4RCA2CA12CA1
SCHEMBL2328723 0.81 ADRB1 (0.55) CA2CA12CA1ADRB1ADRB3
SCHEMBL2323236 0.81 ADRB1 (0.55) CA2CA12CA1ADRB1ADRB3
SCHEMBL2319712 0.81 ADRB1 (0.55) CA2CA12CA1ADRB1ADRB3
SCHEMBL2322514 0.78 CES2 (0.42) GBA1ADRA2CCA2CA12CA1
SCHEMBL2319920 0.78 CES2 (0.42) GBA1ADRA2CCA2CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120302546-A1 NOVEL SULFAMIDES EXHIBITING NEUROPROTECTIVE ACTION AND METHODS FOR USE THEREOF FOX CHASE CHEMICAL DIVERSITY CENTER, INC. (US) 2012-11-29 US claimed
WO-2011097337-A1 NOVEL SULFAMIDES EXHIBITING NEUROPROTECTIVE ACTION AND METHODS FOR USE THEREOF ADVANCED NEURAL DYNAMICS, INC. (US) 2011-08-11 WO claimed
US-20120302546-A1 NOVEL SULFAMIDES EXHIBITING NEUROPROTECTIVE ACTION AND METHODS FOR USE THEREOF FOX CHASE CHEMICAL DIVERSITY CENTER, INC. (US) 2012-11-29 US disclosed
US-20120302546-A1 NOVEL SULFAMIDES EXHIBITING NEUROPROTECTIVE ACTION AND METHODS FOR USE THEREOF FOX CHASE CHEMICAL DIVERSITY CENTER, INC. (US) 2012-11-29 US disclosed
WO-2011097337-A1 NOVEL SULFAMIDES EXHIBITING NEUROPROTECTIVE ACTION AND METHODS FOR USE THEREOF ADVANCED NEURAL DYNAMICS, INC. (US) 2011-08-11 WO disclosed
WO-2011097337-A1 NOVEL SULFAMIDES EXHIBITING NEUROPROTECTIVE ACTION AND METHODS FOR USE THEREOF ADVANCED NEURAL DYNAMICS, INC. (US) 2011-08-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120302546-A1 NOVEL SULFAMIDES EXHIBITING NEUROPROTECTIVE ACTION AND METHODS FOR USE THEREOF GRIK2, GRIK5, GRIN2A GBA1 72/4885MC4R 3320/4885ADRA2C 3470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.